Markert JM - Search Results

1

Expanded spectrum of viral therapy in the treatment of nervous system tumors.

Markert JM, Coen DM, Malick A, Mineta T, Martuza RL. Markert JM, et al. J Neurosurg. 1992 Oct;77(4):590-4. doi: 10.3171/jns.1992.77.4.0590. J Neurosurg. 1992. PMID: 1326612

2

Experimental therapy of human glioma by means of a genetically engineered virus mutant.

Martuza RL, Malick A, Markert JM, Ruffner KL, Coen DM. Martuza RL, et al. Among authors: markert jm. Science. 1991 May 10;252(5007):854-6. doi: 10.1126/science.1851332. Science. 1991. PMID: 1851332

3

Reduction and elimination of encephalitis in an experimental glioma therapy model with attenuated herpes simplex mutants that retain susceptibility to acyclovir.

Markert JM, Malick A, Coen DM, Martuza RL. Markert JM, et al. Neurosurgery. 1993 Apr;32(4):597-603. doi: 10.1227/00006123-199304000-00016. Neurosurgery. 1993. PMID: 8386343

4

CNS tumor therapy by attenuated herpes simplex viruses.

Mineta T, Markert JM, Takamiya Y, Coen DM, Rabkin SD, Martuza RL. Mineta T, et al. Among authors: markert jm. Gene Ther. 1994;1 Suppl 1:S78. Gene Ther. 1994. PMID: 8542424 No abstract available.

5

Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial.

Markert JM, Medlock MD, Rabkin SD, Gillespie GY, Todo T, Hunter WD, Palmer CA, Feigenbaum F, Tornatore C, Tufaro F, Martuza RL. Markert JM, et al. Gene Ther. 2000 May;7(10):867-74. doi: 10.1038/sj.gt.3301205. Gene Ther. 2000. PMID: 10845725 Clinical Trial.

6

Biologic warfare for a good cause: HSV-1 anti-tumor therapy.

Markert JM. Markert JM. Clin Neurosurg. 2004;51:73-80. Clin Neurosurg. 2004. PMID: 15571130 No abstract available.

7

Herpes Simplex Oncolytic Viral Therapy for Malignant Glioma and Mechanisms of Delivery.

Erickson NJ, Stavarache M, Ibrahim T, Kaplitt MG, Markert JM. Erickson NJ, et al. Among authors: markert jm. World Neurosurg. 2024 Dec 20:123595. doi: 10.1016/j.wneu.2024.123595. Online ahead of print. World Neurosurg. 2024. PMID: 39710201 Review.

8

Immunovirotherapy for the Treatment of Glioblastoma and Other Malignant Gliomas.

Estevez-Ordonez D, Chagoya G, Salehani A, Atchley TJ, Laskay NMB, Parr MS, Elsayed GA, Mahavadi AK, Rahm SP, Friedman GK, Markert JM. Estevez-Ordonez D, et al. Among authors: markert jm. Neurosurg Clin N Am. 2021 Apr;32(2):265-281. doi: 10.1016/j.nec.2020.12.008. Epub 2021 Feb 18. Neurosurg Clin N Am. 2021. PMID: 33781507 Free PMC article. Review.

9

The application of genetically engineered herpes simplex viruses to the treatment of experimental brain tumors.

Andreansky SS, He B, Gillespie GY, Soroceanu L, Markert J, Chou J, Roizman B, Whitley RJ. Andreansky SS, et al. Proc Natl Acad Sci U S A. 1996 Oct 15;93(21):11313-8. doi: 10.1073/pnas.93.21.11313. Proc Natl Acad Sci U S A. 1996. PMID: 8876132 Free PMC article. Review.

10

Replication-competent, nonneuroinvasive genetically engineered herpes virus is highly effective in the treatment of therapy-resistant experimental human tumors.

Advani SJ, Chung SM, Yan SY, Gillespie GY, Markert JM, Whitley RJ, Roizman B, Weichselbaum RR. Advani SJ, et al. Among authors: markert jm. Cancer Res. 1999 May 1;59(9):2055-8. Cancer Res. 1999. PMID: 10232586

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

184 results

Search Page

Filters